The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1447
Oral Propranolol (Hemangeol) for Infantile Hemangioma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an oral solution of the nonselective beta-adrenergic blocker propranolol (Hemangeol – Pierre Fabre) for treatment of proliferating infantile hemangiomas.

INFANTILE HEMANGIOMAS — These benign congenital vascular tumors eventually tend to regress spontaneously, but early in life they can grow rapidly and can ulcerate, bleed, cause disfigurement, interfere with respiration or vision, and cause heart failure. Complicated infantile hemangiomas have been treated with systemic corticosteroids. Interferon alfa and vincristine are alternatives.

BACKGROUND — In a report describing 11 children with complicated infantile hemangiomas treated with propranolol (the first child was being treated for an associated condition), the color of the tumor changed within 24 hours from intense red to purple and its texture softened. Subsequently, the tumors continued to regress until they ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Oral Propranolol (Hemangeol) for Infantile Hemangioma
Article code: 1447c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian